Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
95.65 EUR | +1.00% | -0.26% | -4.92% |
May. 23 | BioMérieux, Pfizer to Collaborate on Antimicrobial Resistance Initiative in Malawi | MT |
May. 23 | BioMérieux: initiative against antibiotic resistance in Malawi | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The firm trades with high earnings multiples: 24.5 times its 2024 earnings per share.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.92% | 12.11B | B+ | ||
-5.82% | 8.07B | B- | ||
+5.43% | 5.67B | B | ||
+26.16% | 5.48B | C | ||
-9.58% | 4.12B | C | ||
-59.63% | 2.75B | D+ | ||
+8.44% | 2.62B | - | - | |
-3.70% | 2.33B | B- | ||
+21.00% | 2.11B | C | ||
-7.49% | 1.83B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIM Stock
- Ratings bioMérieux